DK2265589T3 - Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6-antagonister - Google Patents

Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6-antagonister Download PDF

Info

Publication number
DK2265589T3
DK2265589T3 DK09721279.9T DK09721279T DK2265589T3 DK 2265589 T3 DK2265589 T3 DK 2265589T3 DK 09721279 T DK09721279 T DK 09721279T DK 2265589 T3 DK2265589 T3 DK 2265589T3
Authority
DK
Denmark
Prior art keywords
compound
mixture
alkyl
optionally substituted
formula
Prior art date
Application number
DK09721279.9T
Other languages
English (en)
Inventor
Loevezijn Arnold Van
Bakker Wouter I Iwema
Axel Stoit
Agatha A M Rensink
Jennifer Venhorst
Der Neut Martina A W Van
Haan Martin De
Cornelis G Kruse
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Application granted granted Critical
Publication of DK2265589T3 publication Critical patent/DK2265589T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (17)

1. Forbindelse med formlen (1):
eller tautomer, stereoisomer, N-oxid eller farmakologisk acceptabelt salt ifølge et hvilket som helst af de foregående, hvori: Ri er udvalgt fra hydrogen eller en alkyl(Ci_4)-gruppe, eventuelt substitueret med et eller flere halogenatomer eller en hydroxylgruppe, R2 og R3 uafhængigt er udvalgt fra hydrogen, en hydroxylgruppe eller en alkyl(Ci_4)-gruppe eventuelt substitueret med en eller flere substituenter Q, uafhængigt udvalgt fra: halogen, alkyl(Ci-4), alkenyl(Ci_4), alkynyl(Ci-4), CF3, NFb, NHalkyl(C'M), N[alkyl(Ci-4)]2, OH, =0, 0-alkyl(Ci-4) eller OCF3 eller Ri og R2, sammen med carbonatomeme mærket ”a” og ”b” danner en Cs-s-cycloalkylring, eventuelt substitueret med et eller flere halogenatomer, en hydroxylgruppe eller en alkyl(Ci_4)-gruppe eller R2 og R3, sammen med carbonatomet mærket ”b” danner en C3_8-cycloalkyl- eller en C4-8-heterocycloalkylring, eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, R4 og R5 uafhængigt er udvalgt fra hydrogen eller en alkyl(Ci_4)-gruppe eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, eller, R4 og R5 uafhængigt er udvalgt fra en monocyklisk eller kondenseret bicyklisk aromatisk eller heteroaromatisk gruppe, eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, forudsat at Q ikke kan være =0 (keto) på aromatiske ringe, eller R3 og R4, sammen med carbonatomeme mærket ”b” og ”c” danner en C3-8-cycloalkyl- eller en C5-8-heterocycloalkylring, eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, R6 og R7 uafhængigt er udvalgt fra hydrogen, eller en alkyl(Ci-4)-gruppe eventuelt substitueret med et eller flere halogenatomer eller en hydroxylgruppe, eller en dialkyl(Ci-3)-amino-alkyl(Ci-3)-gruppe, eller Ri og R7 uafhængigt er udvalgt fra en monocyklisk eller kondenseret bicyklisk aromatisk eller hetero-aromatisk gruppe eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, eller Ri og R7 uafhængigt er en Cs-s-cycloalkylgruppe eller en Cs-s-heterocycloalkylgruppe eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, eller, R6 og R7, sammen med det nitrogenatom, hvortil de er bundet, danner en Cs-s-heterocycloalkylgruppe eventuelt substitueret med en eller flere substituenter Q, som defineret ovenfor, R§ er 4-aminophenyl, Forudsat, når Ri, R3, R4, Rs og R6 er hydrogen, og R2 og R7 er ethyl, at forbindelsen ikke er en racemisk blanding men en ren enantiomer.
2. Forbindelse ifølge krav 1 med formlen (1), eller tautomer, stereoisomer, N-oxid eller farmakologisk acceptabelt salt ifølge et hvilket som helst af de foregående, hvori: Ri, R4 og R6 er hydrogen R2 og R3 uafhængigt er udvalgt fra hydrogen, en hydroxylgruppe eller en alkyl(Ci-4)-gruppe, eventuelt substitueret med en eller flere substituenter Q*, uafhængigt udvalgt fra: halogen, alkylfC m), NFF, NHalkyl(Ci-4), N[alkyl(Ci-4)]2 eller OH, eller R2 og R3, sammen med det carbonatom, hvortil de er bundet, danner en C3-8-cycloalkyl eller en C5-8-heterocycloalkylring eventuelt substitueret med en eller flere substituenter Q* som defineret ovenfor, Rs er udvalgt fra hydrogen eller en alkyl(Ci-4)-gruppe, eventuelt substitueret med en eller flere substituenter Q* som defineret ovenfor, eller en monocyklisk aromatisk eller heteroaromatisk gruppe eventuelt substitueret med en eller flere substituenter Q* som defineret ovenfor, R7 er udvalgt fra hydrogen, eller en usubstitueret alkyl(Ci_4)-gruppe, eventuelt substitueret med et eller flere halogenatomer eller en hydroxylgruppe, Rs er 4-aminophenyl, Forudsat, når R3 og R5 er hydrogen, og R2 og R7 er ethyl, at forbindelsen ikke er en racemisk blanding men en ren enantiomer.
3. Forbindelse ifølge krav 1 eller krav 2, eller tautomer, stereoisomer, N-oxid eller farmakologisk acceptabelt salt ifølge et hvilket som helst af de foregående, hvor forbindelsen er en optisk aktiv enantiomer.
4. Forbindelse ifølge et hvilket som helst af kravene 1-3 udvalgt fra:
forbindelse 1, (+)-enantiomer, forbindelse 2, (-)-enantiomer, forbindelse 5, forbindelse 8, forbindelse 9, forbindelse 10, eller et farmaceutisk acceptabelt salt ifølge et hvilket som helst af de foregående forbindelser.
5. Forbindelse ifølge et hvilket som helst af kravene 1-3 med formlen
6. Forbindelse ifølge et hvilket som helst af kravene 1-3 med formlen
7. Forbindelse ifølge et hvilket som helst af kravene 1-3 med formlen
8. Forbindelse ifølge et hvilket som helst af kravene 1-3 med formlen
9. Forbindelse ifølge et hvilket som helst af kravene 1-3 med formlen
10. Farmaceutisk sammensætning, der omfatter en forbindelse ifølge et hvilket som helst af kravene 1-9 eller et farmakologisk acceptabelt salt deraf, og en farmaceutisk acceptabel bærer.
11. Medikament, der omfatter en forbindelse ifølge et hvilket som helst af kravene 1 -9, eller et farmakologisk acceptabelt salt deraf.
12. Medikament ifølge krav 11, der endvidere omfatter: mindst ét yderligere terapeutisk middel.
13. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1-9 til fremstilling af en farmaceutisk sammensætning til behandling eller profylakse af Parkinsons sygdom, Huntingtons chorea, skizofreni, angst, depression, manisk depression, psykoser, epilepsi, obsessive-kompulsive tilstande, stemningsforstyrrelser, migræne, Alzheimers sygdom, aldersrelateret kognitiv tilbagegang, mild kognitiv svækkelse, søvnforstyrrelser, spiseforstyrrelser, anoreksi, bulimi, overspisning, panikanfald, akatisi, ADHD, ADD, afvænning fra misbrug af kokain, ethanol, nikotin eller benzodiazepiner, smerte, forstyrrelser forbundet med rygradstraumer eller hovedlæsion, hydrocefali, funktionel tarmsygdom, irritable tarmsyndrom, fedme eller type-2 diabetes.
14. Forbindelser med den almene formel (lx):
hvori A enten repræsenterer halogen eller S-alkyl(Ci_4), og de andre symboler har betydninger som anført i krav 1, og tautomer og stereoisomerer deraf, hvor sådanne forbindelser er anvendelige i syntesen af forbindelser med den almene formel (1).
15. Fremgangsmåde til fremstilling af forbindelser ifølge krav 1 med formlen (1), hvori R7 er hydrogen, der dermed har formlen (Γ), hvori alle symboler har betydningen som anført i krav 1, hvilken fremgangsmåde omfatter følgende trin: (i) etablering af kontakt mellem en forbindelse med formlen (X), opnået ved etablering af en reaktion mellem en forbindelse med formlen (IX) og et alkylhalogenid, eksempelvis methyliodid, med et pyrazolin i nærvær af en base for at give en forbindelse med formlen (n (ii) etablering af kontakt mellem en forbindelse med formlen (P) og et sulfonylhalogenid med formlen Rs-SCp-X, hvori X er Br, Cl eller F, i et aprotisk opløsningsmiddel, såsom dichlormethan, i nærvær af en base, såsom diisopropylethyl-amin,
16. Forbindelse ifølge et hvilket som helst af kravene 1-9 til anvendelse som et medikament.
17. Forbindelse ifølge et hvilket som helst af kravene 1-9 til anvendelse i en fremgangsmåde til behandling eller profylakse af Parkinsons sygdom, Huntingtons chorea, skizofreni, angst, depression, manisk depression, psykoser, epilepsi, obsessive-kompulsive tilstande, humørforstyrrelser, migræne, Alzheimers sygdom, aldersrelateret kognitiv tilbagegang, mild kognitiv svækkelse, søvnforstyrrelser, spiseforstyrrelser, anoreksi, bulimi, overspisning, panikanfald, akatisi, ADHD, ADD, afvænning fra misbrug af kokain, ethanol, nikotin eller benzodiazepiner, smerte, forstyrrelser forbundet med rygradstraumer eller hovedlæsion, hydrocefali, funktionel tarmsygdom, irritabel tarmsyndrom, fedme eller type-2 diabetes.
DK09721279.9T 2008-03-18 2009-03-17 Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6-antagonister DK2265589T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3746308P 2008-03-18 2008-03-18
EP08152873 2008-03-18
PCT/EP2009/053133 WO2009115515A1 (en) 2008-03-18 2009-03-17 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists

Publications (1)

Publication Number Publication Date
DK2265589T3 true DK2265589T3 (da) 2016-03-21

Family

ID=39639064

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09721279.9T DK2265589T3 (da) 2008-03-18 2009-03-17 Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6-antagonister
DK13161112.1T DK2610247T3 (da) 2008-03-18 2009-03-17 Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6- antagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13161112.1T DK2610247T3 (da) 2008-03-18 2009-03-17 Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6- antagonister

Country Status (29)

Country Link
US (3) US8563723B2 (da)
EP (2) EP2265589B1 (da)
JP (1) JP5504252B2 (da)
KR (1) KR101623357B1 (da)
CN (2) CN104003937A (da)
AR (1) AR070898A1 (da)
AU (1) AU2009226956C1 (da)
BR (1) BRPI0908738A8 (da)
CA (1) CA2717922A1 (da)
CO (1) CO6290679A2 (da)
CR (1) CR11742A (da)
DK (2) DK2265589T3 (da)
DO (2) DOP2010000276A (da)
EA (1) EA023176B1 (da)
EC (1) ECSP10010476A (da)
ES (2) ES2577867T3 (da)
HK (2) HK1201823A1 (da)
IL (1) IL207846A0 (da)
MX (1) MX2010010299A (da)
MY (1) MY155318A (da)
NZ (1) NZ587743A (da)
PH (1) PH12013502376B1 (da)
PL (2) PL2265589T3 (da)
PT (1) PT2610247T (da)
SG (1) SG183688A1 (da)
TW (1) TWI557110B (da)
UA (1) UA105629C2 (da)
WO (1) WO2009115515A1 (da)
ZA (1) ZA201006272B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
WO2013025805A1 (en) * 2011-08-15 2013-02-21 University Of Utah Research Foundation Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
ES2605856T3 (es) 2012-11-16 2017-03-16 Bristol-Myers Squibb Company Moduladores GPR40 de dihidropirazol
SG11201503562PA (en) * 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
BR112015010779A2 (pt) * 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de di-hidropirazol gpr40
CN106660968B (zh) * 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
WO2016025637A1 (en) 2014-08-12 2016-02-18 Loyola University Of Chicago Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药（江苏）有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
WO2021069567A1 (en) 2019-10-09 2021-04-15 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
EP4178982A1 (en) 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2442245C (en) * 2001-09-21 2010-03-30 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
SA07280510B1 (ar) * 2006-09-22 2012-02-07 سولفاي فارماسوتيكالز بي . في سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5

Also Published As

Publication number Publication date
ZA201006272B (en) 2011-05-25
CN102036967A (zh) 2011-04-27
TWI557110B (zh) 2016-11-11
US8563723B2 (en) 2013-10-22
KR101623357B1 (ko) 2016-05-23
CO6290679A2 (es) 2011-06-20
AU2009226956A1 (en) 2009-09-24
CN102036967B (zh) 2014-10-15
US8901108B2 (en) 2014-12-02
CA2717922A1 (en) 2009-09-24
NZ587743A (en) 2012-06-29
ES2577867T3 (es) 2016-07-19
WO2009115515A1 (en) 2009-09-24
EP2265589A1 (en) 2010-12-29
EA201071083A1 (ru) 2011-04-29
AU2009226956B2 (en) 2013-05-23
CN104003937A (zh) 2014-08-27
MY155318A (en) 2015-09-30
US9126942B2 (en) 2015-09-08
ES2565184T3 (es) 2016-04-01
ECSP10010476A (es) 2010-10-30
EP2265589B1 (en) 2016-01-27
DOP2010000276A (es) 2010-11-15
SG183688A1 (en) 2012-09-27
EA023176B1 (ru) 2016-05-31
DK2610247T3 (da) 2016-06-13
DOP2010000277A (es) 2011-01-31
PT2610247T (pt) 2016-07-07
US20140011775A1 (en) 2014-01-09
EP2610247B1 (en) 2016-05-25
UA105629C2 (uk) 2014-06-10
EP2610247A1 (en) 2013-07-03
HK1152708A1 (en) 2012-03-09
PL2265589T3 (pl) 2016-06-30
AR070898A1 (es) 2010-05-12
US20110046171A1 (en) 2011-02-24
IL207846A0 (en) 2010-12-30
CR11742A (es) 2011-03-03
JP5504252B2 (ja) 2014-05-28
BRPI0908738A8 (pt) 2017-10-10
PL2610247T3 (pl) 2017-02-28
TW200942519A (en) 2009-10-16
PH12013502376A1 (en) 2015-01-12
US20150051239A1 (en) 2015-02-19
PH12013502376B1 (en) 2015-01-12
MX2010010299A (es) 2010-12-15
AU2009226956A8 (en) 2010-09-23
HK1201823A1 (en) 2015-09-11
BRPI0908738A2 (pt) 2017-06-13
AU2009226956C1 (en) 2014-03-06
JP2011517443A (ja) 2011-06-09
KR20100136504A (ko) 2010-12-28

Similar Documents

Publication Publication Date Title
DK2265589T3 (da) Arylsulfonylpyrazolincarboxamidinderivater som 5-ht6-antagonister
AU2007298987B2 (en) Sulfonylpyrazoline carboxamidine derivatives as 5-HT6 antagonists
UA80184C2 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
EP3027613B1 (en) Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
US20220380345A1 (en) Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives having multimodal activity against pain
EP3365338B1 (en) Substituted morpholine derivatives having activity against pain
EP2870164A1 (en) IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS
EP2986616B1 (en) Tricyclic triazolic compounds as sigma receptors ligans